1921
Volume 92, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Atovaquone-proguanil (AP) and artemether-lumefantrine (AL) are both treatments for uncomplicated malaria, but comparative clinical trials are lacking. We performed a retrospective analysis, comparing treatment failure and fever clearance time in non-immune travelers with uncomplicated malaria, treated with AP or AL. Sixty-nine patients were included during 2001–2013: 44 in the AP group and 25 in the AL group. Treatment failure was observed in 6 of 44 (13.6%) and 1 of 25 (4.0%) patients in the AP and AL groups, respectively. Six treatment failures were observed in travelers from West Africa. Fever clearance time was 44 ± 23 h in AL group versus 77 ± 28 h in AP group, ( < 0.001). Hospitalization time was significantly shorter in the AL group; 3.8 + 1.3 versus 5.1 + 2.8 days in the AP group ( = 0.04) In conclusion, travelers with uncomplicated malaria recover faster on AL than on AP. The AL should probably be the drug of choice for this population.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0249
2015-01-07
2017-11-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/92/1/13.html?itemId=/content/journals/10.4269/ajtmh.14-0249&mimeType=html&fmt=ahah

References

  1. Schwartz E, Schwartz E, , 2009. Malaria in travelers: epidemiology, clinical aspects and treatment. , ed. Tropical Diseases in Travelers. New York: Wiley-Blackwell.[Crossref]
  2. Leder K, Black J, O'Brien D, Greenwood Z, Kain KC, Schwartz E, Brown G, Torresi J, , 2004. Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 39: 11041112.[Crossref]
  3. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L, , 2010. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis 51: e82e89.[Crossref]
  4. Sutherland CJ, Laundy M, Price N, Burke M, Fivelman QL, Pasvol G, Klein JL, Chiodini PL, , 2008. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Malar J 7: 240.[Crossref]
  5. Wurtz N, Pascual A, Marin-Jauffre A, Bouchiba H, Benoit N, Desbordes M, Martelloni M, Pommier de Santi V, Richa G, Taudon N, Pradines B, Briolant S, , 2012. Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast. Malar J 11: 146.[Crossref]
  6. Perry TL, Pandey P, Grant JM, Kain KC, , 2009. Severe atovaquone-resistant Plasmodium falciparum malaria in a Canadian traveler returned from the Indian subcontinent. Open Med 3: e10e16.[Crossref]
  7. Hitani A, Nakamura T, Ohtomo H, Nawa Y, Kimura M, , 2006. Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan. J Infect Chemother 12: 277282.[Crossref]
  8. Bouchaud O, Monlun E, Muanza K, Fontanet A, Scott T, Goetschel A, Chulay JD, Le Bras J, Danis M, Le Bras M, Coulaud JP, Gentilini M, , 2000. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Am J Trop Med Hyg 63: 274279.
  9. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G, , 2002. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 1: 1.[Crossref]
  10. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G, Richter J, , 2004. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis 190: 15411546.[Crossref]
  11. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ, , 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomized trial. Lancet 376: 16471657.[Crossref]
  12. WHO, 2010. Guidelines for the Treatment of Malaria. Second edition. Available at: http://www.who.int/malaria/publications/atoz/9789241547925/en/. Accessed July 18, 2014.
  13. Mizuno Y, Kato Y, Kudo K, Kano S, , 2009. First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria. Jpn J Infect Dis 62: 139141.
  14. Farnert A, Ursing J, Tolfvenstam T, Rono J, Karlsson L, Sparrelid E, Lindegardh N, , 2012. Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveler with Plasmodium falciparum malaria after returning from Tanzania. Malar J 11: 176.[Crossref]
  15. Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, Socheat D, Fandeur T, Annerberg A, Christophel EM, Ringwald P, , 2006. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health 11: 18001807.[Crossref]
  16. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, Bricaire F, Gay F, Burchard GD, Andriano K, Lefevre G, De Palacios PI, Genton B, , 2008. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg 78: 241247.
  17. Neuberger A, Zaulan O, Tenenboim S, Vernet S, Pex R, Held K, Urman M, Garpenfeldt K, Schwartz E, , 2011. Malaria among patients and aid workers consulting a primary healthcare centre in Leogane, Haiti, November 2010 to February 2011 — a prospective observational study. Euro Surveill 16: pii=19829. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19829.
  18. van Agtmael M, Bouchaud O, Malvy D, Delmont J, Danis M, Barette S, Gras C, Bernard J, Touze JE, Gathmann I, Mull R, , 1999. The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travelers returning from the Tropics to The Netherlands and France. Int J Antimicrob Agents 12: 159169.[Crossref]
  19. Bouchaud O, Muhlberger N, Parola P, Calleri G, Matteelli A, Peyerl-Hoffmann G, Mechai F, Gautret P, Clerinx J, Kremsner PG, Jelinek T, Kaiser A, Beltrame A, Schmid ML, Kern P, Probst M, Bartoloni A, Weinke T, Grobusch MP, , 2012. Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study. Malar J 11: 212.[Crossref]
  20. Schwartz E, Bujanover S, Kain KC, , 2003. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 37: 450451.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0249
Loading
/content/journals/10.4269/ajtmh.14-0249
Loading

Data & Media loading...

  • Received : 23 Apr 2014
  • Accepted : 11 Jun 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error